8Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin [J]. J Antimicrob Chemother, 1996, 37:209-222
9Elting IS, Rubenstein EB, Kurtin D, et al. Mississippi mud in the 1990s.Risks and outcomes of vancomycin-associated toxicity in general oncology practice[J ]. Cancer, 1998, 83( 12):2597-2607
10Beringer PM, Wong-Beringer A, Rho JP. Economic aspects of antibacterial adverse effect[J].Pharmacoeconomics, 1998, 13(Pt1):35--49
